Reflections on the DESTINY-Breast04 trial | Patricia LoRusso

(5:2)

DESTINY-Breast04: T-DXd provides significant improvement in OS + PFS in HER2-low mBC

(5:11)

DESTINY-Breast04: T-DXd in HER2-low breast cancer regardless of molecular markers

(2:31)

ASCO Daily News 2022 Plenary Update - LBA3: DESTINY-Breast04

(3:31)

DESTINY-Breast04: A ground-breaking trial in HER2-low breast cancer

(1:8)

DESTINY-Breast04: T-DXd for patients with HER2-low mBC

(56)

Patient-reported outcomes from DESTINY-Breast04

(2:30)

ASCO2022 DESTINY BREAST 04 - How can we interpret a trial without pre or post treatment information?

(32:15)

DESTINY-Breast04: practice-changing results for HER2-low breast cancer

(2:1econd)

Detailed safety analysis from the DESTINY-Breast04 trial

(6:33)

DESTINY-Breast04 Study: T-DXd Breakthrough for HER2-Low Breast Cancer Treatment

(3:28)

DESTINY-Breast04 Study Discussion - OncBrothers (Rohit and Rahul Gosain) with Dr. Shanu Modi

(20:3)

Biomarker-based personalization for HER2-low breast cancer treatment in DESTINY-Breast04

(45)

Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients

(5:57)

DESTINY-Breast04: exploring T-DXd and IO combinations in HER2-low breast cancer

(1:14)

DESTINY Breast 04 Data and How It Impacts the Current Pathology Landscape

(1:28)

Trastuzumab Cardiotoxicity in DESTINY-Breast04 Trial

(8:49)

ASCO 2022: DESTINY-Breast04, PALOMA-2, rEECur

(4:18)

DESTINY-Breast04 and Other Key Breast Cancer Studies at ASCO22

(31:4)

Comment: Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer pts

(1:17)